Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

BACKGROUND: We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-...

Descripción completa

Detalles Bibliográficos
Autores principales: Logunov, Denis Y, Dolzhikova, Inna V, Zubkova, Olga V, Tukhvatulin, Amir I, Shcheblyakov, Dmitry V, Dzharullaeva, Alina S, Grousova, Daria M, Erokhova, Alina S, Kovyrshina, Anna V, Botikov, Andrei G, Izhaeva, Fatima M, Popova, Olga, Ozharovskaya, Tatiana A, Esmagambetov, Ilias B, Favorskaya, Irina A, Zrelkin, Denis I, Voronina, Daria V, Shcherbinin, Dmitry N, Semikhin, Alexander S, Simakova, Yana V, Tokarskaya, Elizaveta A, Lubenets, Nadezhda L, Egorova, Daria A, Shmarov, Maksim M, Nikitenko, Natalia A, Morozova, Lola F, Smolyarchuk, Elena A, Kryukov, Evgeny V, Babira, Vladimir F, Borisevich, Sergei V, Naroditsky, Boris S, Gintsburg, Alexander L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471804/
https://www.ncbi.nlm.nih.gov/pubmed/32896291
http://dx.doi.org/10.1016/S0140-6736(20)31866-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471804/
https://www.ncbi.nlm.nih.gov/pubmed/32896291
http://dx.doi.org/10.1016/S0140-6736(20)31866-3

Ejemplares similares